Cargando…
Rapamycin-filgrastim combination therapy ameliorates portal hypertension-induced splenomegaly: Role of β actin and S100A9 proteins modulation
OBJECTIVE(S): Thioacetamide (TAA) was administered to induce an animal model of liver disease with secondary splenomegaly to assess the mechanisms underlying the effects of rapamycin and filgrastim when taken separately or in combination on the biochemical and histopathological aspects of the liver...
Autores principales: | Abdelrahman, Shaimaa A., Abdelfatah, Mohammed M., Keshta, Akaber T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mashhad University of Medical Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320204/ https://www.ncbi.nlm.nih.gov/pubmed/35949314 http://dx.doi.org/10.22038/IJBMS.2022.64034.14101 |
Ejemplares similares
-
Rapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway
por: Chen, Yunyang, et al.
Publicado: (2016) -
Variceal Bleed and Portal Hypertensive Gastropathy in a Noncirrhotic Patient with Isolated Splenomegaly
por: Hasan, S. M. Mahmudul, et al.
Publicado: (2020) -
Outcomes of partial splenic embolization in patients with massive splenomegaly due to idiopathic portal hypertension
por: Ozturk, Omer, et al.
Publicado: (2016) -
Distribution characteristics of cells in splenomegaly due to hepatitis B-related cirrhotic portal hypertension and their clinical importance
por: Han, Xiaoyu, et al.
Publicado: (2018) -
Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics
por: Sörgel, Fritz, et al.
Publicado: (2015)